SCHEMBL16648971

SCHEMBL16648971

N#Cc1ccnc(N2CCC(c3cc(N)[nH]n3)CC2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCAT P04180 1/20 0.48
HRH3 Q9Y5N1 1/20 0.43
LRRK2 Q5S007 5/20 0.42
MALT1 Q9UDY8 1/20 0.42
USP30 Q70CQ3 1/20 0.41
HTR7 P34969 1/20 0.39
CHRM4 P08173 1/20 0.38
PAK4 O96013 1/20 0.38
PAK1 Q13153 1/20 0.38
PANK3 Q9H999 1/20 0.38
DPP4 P27487 1/20 0.38
PRKD1 Q15139 1/20 0.37
PRKD2 Q9BZL6 1/20 0.37
MAP3K12 Q12852 2/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
PARP1 P09874 1/20 0.36
TNK2 Q07912 1/20 0.36
TNK1 Q13470 1/20 0.36
AVPR1A P37288 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16664264 0.84 LCAT (0.46) LCATPANK3DPP4PARP1
SCHEMBL16648414 0.82 LCAT (0.46) LCATPAK4PAK1AVPR1A
SCHEMBL16648709 0.81 PARP1 (0.44) LCATHRH3USP30PARP1AVPR1A
SCHEMBL16648729 0.80 DRD2 (0.52) LCATLRRK2USP30PARP1
SCHEMBL16649038 0.80 MALT1 (0.50) LCATHRH3LRRK2MALT1USP30
SCHEMBL16648541 0.79 AVPR1A (0.47) LCATAVPR1A
SCHEMBL16648821 0.79 LCAT (0.48) LCATHRH3LRRK2HTR7PAK4
SCHEMBL16648416 0.79 ADRB1 (0.54) LCATHRH3CHRM4DPP4
SCHEMBL16664265 0.78 LCAT (0.48) LCATUSP30PAK4PAK1PARP1
SCHEMBL16648647 0.77 LCAT (0.49) LCAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2862861-B1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-01-06 EP disclosed
EP-2862861-B1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-01-06 EP disclosed
US-9150575-B2 Piperidinylpyrazolopyridine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-10-06 US disclosed
US-9150575-B2 Piperidinylpyrazolopyridine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-10-06 US disclosed
CN-104781257-A Piperidinylpyrazolopyridine derivative DAIICHI SANKYO CO LTD 2015-07-15 CN disclosed
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-06-04 US disclosed
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-06-04 US disclosed
EP-2862861-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-04-22 EP disclosed
EP-2862861-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE LCAT, LPL, LCLAT1 LCAT 1/4885HRH3 3681/4885LRRK2 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.